NCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT02846766 2018-08-02
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
University of California, San Diego
Phase 2 Withdrawn